About ENDRA Life Sciences Inc. - Common Stock (NDRA)
Endra Life Sciences Inc is a pioneering medical technology company focused on enhancing non-invasive imaging techniques for better diagnosis and treatment guidance in healthcare. The company specializes in the development of its innovative Thermo Acoustic Imaging technology, which combines ultrasound and thermal imaging to provide real-time insights into tissue and organ function. By enabling clinicians to visualize metabolic conditions more effectively, Endra aims to improve patient outcomes in various areas, including liver health and cancer detection, while also streamlining the imaging process in medical practices. Read More
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer in medical imaging and digital innovation, is redefining the intersection of healthcare technology and decentralized finance through its groundbreaking Thermo Acoustic Enhanced UltraSound (TAEUS®) platform and its newly launched Digital Asset Treasury (DAT) strategy. Together, these initiatives position ENDRA as one of the most forward-looking companies in both the medtech and blockchain arenas.
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced a significant step in its digital asset strategy with the commencement of staking its holdings of HYPE, the native token of the Hyperliquid ecosystem.
The Viral Threat Hiding in Plain Sight: Between August 2024 and July 2025, the CDC’s NoroSTAT system recorded 2,675 norovirus outbreaks across the United States. A genetic shift has emerged: the GII.17 strain has overtaken the long-dominant GII.4 lineage , now responsible for roughly 75 percent of reported cases . Health officials warn this strain replacement increases outbreak frequency and severity, as current cleaning and immunity defenses are quickly becoming outdated. Why It Matters
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), has successfully closed its previously announced private investment in public equity ("PIPE") financing led by institutional and cryptocurrency investors.
As we await the opening of the US market on Tuesday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9 million in commitments for a private placement (the “Offering”) led by leading institutional and cryptocurrency investors. The proceeds will be used to launch a digital asset treasury (“DAT”) strategy directed at the highest conviction holdings of Arca Investment Management, LLC (“Arca”) in the DeFi sector, beginning with the cryptocurrencies of the pioneering decentralized exchanges and protocols, with a focus on perpetual futures such as HYPE.
ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three and six months ended June 30, 2025.
The session on Wednesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top gainers and losers in today's session.
